AOD-9604 Research Guide 2026: HGH 176-191 Fat Loss
AOD-9604 is a synthetic 16-residue modified C-terminal hGH peptide, conventionally described as Tyr–hGH(177–191). Adding tyrosine to an already 16-residue “176–191” fragment would incorrectly imply 17 residues. It was developed to investigate lipid-metabolism effects separately from full human growth hormone.
The useful evidence consists of specific rat/mouse experiments and a discontinued obesity-development program. These findings do not establish clinical fat-loss efficacy or equivalence with full hGH.
What is AOD-9604?
AOD-9604 is a modified hGH C-terminal peptide with 16 residues, commonly represented as Tyr plus hGH residues 177–191. “HGH 176–191 fragment” is used as shorthand, but the exact sequence and modifications should be recorded. FDA’s 2024 characterization review also describes a disulfide bridge between the two cysteines; oxidation state and salt form are part of the material’s identity.
Related research compounds are not automatically AOD-9604. In particular, the cited 2000 oral paper by Heffernan et al. studied AOD9401, while Ng et al. (2000) directly studied AOD9604 in Zucker rats. Match the working lot to the paper’s material and analytical report.
Mechanism of Action
The primary studies support model-specific lipid-metabolism findings. They do not establish a complete direct-receptor mechanism for AOD-9604.
β3-Adrenergic Dependence Is Not Direct Agonism
Heffernan et al. (2001) compared obese and β3-adrenoceptor-knockout mice. Chronic metabolic responses depended partly on the β3 system, while an acute fat-oxidation response remained in knockout animals. Receptor dependence in a knockout experiment does not demonstrate that AOD-9604 directly binds or activates β3 receptors.
Comparison With Full hGH
Ng et al. (2000) reported that oral AOD9604 reduced weight gain in obese Zucker rats. The reported insulin-sensitivity finding was no adverse effect compared with the effect of intact hGH, not an established improvement over untreated controls. Insulin sensitivity is itself a carbohydrate-metabolism endpoint, so a blanket statement that AOD9604 cannot affect carbohydrate metabolism would be too broad. Keep these results assigned to that rat model.
Claims Outside Lipid Metabolism
Do not infer cartilage efficacy or a CB1 mechanism from a lipid-metabolism paper. Additional mechanisms require their own material- and model-specific experiments.
Foundational Studies and Clinical Development
2000 - AOD9604 in obese Zucker rats: Ng et al. reported oral metabolic findings, including weight-gain and insulin-sensitivity endpoints.
2000 - related AOD9401 paper: Heffernan et al.’s oral-fragment experiment concerns a different compound and should be labelled accordingly.
2001 - β3 knockout comparison: Heffernan et al. tested AOD9604 and full hGH in obese and β3-adrenoceptor-knockout mice.
Subsequent clinical development: the obesity program did not establish the efficacy needed for continuation. FDA’s advisory materials review the clinical record and material-characterization concerns; a completed study does not itself constitute therapeutic approval.
Safety, Limitations, and Regulatory Status
AOD-9604 should not be presented as an established obesity treatment. FDA’s advisory review describes gaps in evidence and characterization, and a GRAS-related food-use statement is different from drug approval.
The TGA scheduling decision concerns regulation, not proof of therapeutic approval or a blanket permission for a supplier’s formulation. Assess the exact jurisdiction and product rather than extrapolating from a short clinical safety summary.
Conclusion
AOD-9604 is a modified hGH fragment with lipid-metabolism findings in defined rat and mouse models. Those results are separate from the discontinued obesity-development program, which did not establish clinical weight-loss efficacy. The cited experiments do not demonstrate universal isolation from GH-axis effects across species or formulations. For material- and model-specific metabolic work, see our research disclaimer and storage reference.
Source this peptide for your research
Order AOD9604Research source
Source AOD9604 for your research
Compare available sizes and check the matching batch certificate before ordering.
View productFrequently Asked Questions
Is AOD-9604 legal to purchase and study?
Requirements depend on jurisdiction and the specific product. AOD-9604 research availability or a food-use GRAS statement does not establish approval as an obesity drug. The cited TGA scheduling material is not a complementary-medicine marketing authorization.
How does AOD-9604 differ from full human growth hormone?
AOD-9604 is a modified 16-residue C-terminal hGH peptide, commonly described as Tyr–hGH(177–191), rather than full 191-residue growth hormone. Specific rat/mouse experiments investigated metabolic endpoints separately from hGH. Their findings do not prove universal absence of endocrine effects across species or formulations.
Is AOD-9604 orally active?
Ng et al. (2000) reported oral AOD9604 effects in obese Zucker rats. The cited Heffernan 2000 oral paper studied related AOD9401, not AOD9604. Animal oral activity does not establish a validated human oral regimen or equivalence across preparations.
What is the half-life of AOD-9604?
The sources listed here do not establish a universal half-life for every research AOD-9604 preparation. A defensible PK statement must identify the species, route, formulation and measured analyte; a delayed lipid endpoint is not the parent-peptide half-life.
Where can researchers obtain research-grade AOD-9604?
Review the lot-specific report for the exact sequence, modifications, HPLC method/trace and interpreted MS result. A compatible intact mass supports composition but is not complete sequence confirmation. If stock concentration matters, obtain a quantitative target-content basis; HPLC area purity is separate from net content. Select acceptance criteria for the model rather than assuming one percentage measures every quality attribute.
Scientific References
- Ng et al. 2000. AOD9604 metabolic study in Zucker rats. PMID: 11146367 - Primary source[PubMed Reference]
- Heffernan et al. 2001. AOD9604 and β3-adrenoceptor knockout mice. PMID: 11713213 - Primary source[PubMed Reference]
- Heffernan et al. 2000. Related oral AOD9401 study; not AOD9604. PMID: 10950816 - Primary source[PubMed Reference]
- FDA 2024 advisory review of AOD-9604 - Primary source
- TGA 2015 scheduling decision (not marketing authorization) - Primary source
Related Research Peptides
Tirzepatide
